• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部放疗在诱导期前后会延迟多发性骨髓瘤患者的干细胞动员和采集。

Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma Patients.

机构信息

Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

Department of Radiation Oncology, University Hospitals Gießen and Marburg (UKGM), Gießen, Germany; FB20 Medicine, Philipps-University Marburg, Marburg, Germany.

出版信息

Transplant Cell Ther. 2021 Oct;27(10):876.e1-876.e11. doi: 10.1016/j.jtct.2021.06.025. Epub 2021 Jun 30.

DOI:10.1016/j.jtct.2021.06.025
PMID:34214737
Abstract

In multiple myeloma, local radiation therapy (RT) of osseous lesions before peripheral blood stem cell (PBSC) mobilization is assumed to impair the PBSC mobilization and collection. However, the results of previously published studies are inconsistent and do not evaluate detailed metrics of RT and PBSC outcome parameters. In total, 352 patients undergoing PBSC mobilizations and RT in first-line treatment were evaluated. Patients were grouped into RT (n = 283) and no RT (n = 69) before PBSC mobilization. Except for the International Staging System score, both groups were homogeneous regarding the first diagnosis characteristics, first-line treatments, and response parameters. RT metrics (RT yes versus no, volume of irradiated hematopoietic bone marrow [BM], biologically equivalent doses in 2 Gy fractions [EQD2]) were analyzed for the following PBSC outcome parameters: achievement of the PBSC collection goal, CD34+ cell collection yield, duration of the mobilization phase, and number of leukapheresis (LP) sessions to reach the collection goal. No statistically significant differences in the percentage of collection failures to reach at least 3 sufficient PBSC transplants were identified comparing patients with (n = 32 [11%]) and without RT (n = 4 [6%]) before PBSC mobilization (P = .265). However, patients with RT before PBSC mobilization showed a significant prolongation of the PBSC mobilization (median 1 day, P =.026) and required a higher number of LP sessions to reach the collection goal (median 1 LP, P < .001) compared with patients who received RT after PBSC mobilization. Moreover, patients with RT before PBSC mobilization reached a significantly lower CD34+ cell collection result (mean 8.94 versus 9.81 × 10/kg body weight [bw], P = .002). No correlation was identified between the overall CD34+ cell yield and the volume of irradiated hematopoietic BM or EQD2, respectively. In the RT before PBSC mobilization group, patients who required more than 1 LP session to reach the PBSC collection goal after RT had a significantly higher percentage of radiated hematopoietic BM compared to those who required only 1 LP session (mean 9.7% versus 7.2%, P = .002). Overall, our study indicates a negative impact of RT on PBSC mobilization and collection. Apart from emergency settings, it might be beneficial to postpone RT to a post-PBSC collection time point. © 2021 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

摘要

在多发性骨髓瘤中,人们认为在采集外周血干细胞 (PBSC) 之前对骨病变进行局部放射治疗 (RT) 会损害 PBSC 的动员和采集。然而,先前发表的研究结果并不一致,并且没有评估 RT 和 PBSC 结果参数的详细指标。本研究共评估了 352 例在一线治疗中接受 PBSC 动员和 RT 的患者。患者被分为 RT 组 (n = 283) 和无 RT 组 (n = 69)。除国际分期系统评分外,两组在首次诊断特征、一线治疗和反应参数方面均具有同质性。分析了 RT 指标 (RT 是与否、照射造血骨髓的体积、2 Gy 分数的生物等效剂量 [EQD2]) 对以下 PBSC 结果参数的影响:达到 PBSC 采集目标、CD34+细胞采集产量、动员阶段持续时间以及达到采集目标所需的白细胞分离术 (LP) 次数。在比较接受 PBSC 动员前有 (n = 32 [11%]) 和无 RT (n = 4 [6%]) 的患者,发现达到至少 3 次足够 PBSC 移植的采集失败百分比没有统计学显著差异 (P =.265)。然而,与接受 PBSC 动员后接受 RT 的患者相比,在 PBSC 动员前接受 RT 的患者 PBSC 动员明显延长 (中位数 1 天,P =.026),并且需要更多的 LP 次数才能达到采集目标 (中位数 1 LP,P <.001)。此外,在 PBSC 动员前接受 RT 的患者 CD34+细胞采集结果明显较低 (平均 8.94 与 9.81×10/kg 体重 [bw],P =.002)。未发现整体 CD34+细胞产量与照射造血 BM 或 EQD2 体积之间存在相关性。在 PBSC 动员前接受 RT 的患者中,需要进行超过 1 次 LP 才能达到 PBSC 采集目标的患者与仅需要进行 1 次 LP 的患者相比,照射造血 BM 的比例明显更高 (平均 9.7%比 7.2%,P =.002)。总的来说,我们的研究表明 RT 对 PBSC 动员和采集有负面影响。除紧急情况外,将 RT 推迟到 PBSC 采集后时间点可能会更有益。

相似文献

1
Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma Patients.局部放疗在诱导期前后会延迟多发性骨髓瘤患者的干细胞动员和采集。
Transplant Cell Ther. 2021 Oct;27(10):876.e1-876.e11. doi: 10.1016/j.jtct.2021.06.025. Epub 2021 Jun 30.
2
Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients.临床参数和诱导方案对多发性骨髓瘤患者外周血干细胞动员及采集的影响
Transfus Med Hemother. 2023 Jun 5;50(5):382-395. doi: 10.1159/000530056. eCollection 2023 Oct.
3
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.来那度胺、硼替佐米和地塞米松联合依鲁替尼或伊沙妥昔单抗治疗初诊多发性骨髓瘤患者后的干细胞采集:来自 GMMG-HD6 和 -HD7 试验的单中心经验。
BMC Cancer. 2023 Nov 21;23(1):1132. doi: 10.1186/s12885-023-11507-9.
4
Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.多发性骨髓瘤患者外周血中浆细胞和造血祖细胞的同时动员。
J Hematother. 1996 Aug;5(4):339-49. doi: 10.1089/scd.1.1996.5.339.
5
Low-dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease.低剂量环磷酰胺可有效动员自身免疫性疾病患者的外周血干细胞。
Eur J Haematol. 2016 Jul;97(1):78-82. doi: 10.1111/ejh.12686. Epub 2015 Oct 27.
6
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.达雷妥尤单抗、硼替佐米、沙利度胺和地塞米松方案与硼替佐米、环磷酰胺和地塞米松方案用于新诊断多发性骨髓瘤患者自体干细胞采集的比较
Transfus Med Hemother. 2023 Mar 24;50(5):371-381. doi: 10.1159/000529691. eCollection 2023 Oct.
7
Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.影响多发性骨髓瘤患者外周血干细胞采集的因素。
Bone Marrow Transplant. 1996 Jun;17(6):937-41.
8
Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction.聚乙二醇化非格司亭与非格司亭用于新型药物诱导后多发性骨髓瘤干细胞动员的比较
Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):174-179. doi: 10.1016/j.clml.2017.12.010. Epub 2018 Jan 5.
9
Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma.采用大容量白细胞分离术采集更多多发性骨髓瘤患者的造血祖细胞。
Leuk Lymphoma. 1998 Feb;28(5-6):501-8. doi: 10.3109/10428199809058357.
10
Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection.化疗法动员和 G-CSF 给药在成功造血干细胞采集中的协同作用。
Biol Blood Marrow Transplant. 2018 Jun;24(6):1281-1288. doi: 10.1016/j.bbmt.2018.01.007. Epub 2018 Jan 17.

引用本文的文献

1
An approach to autologous stem cell mobilization: trying to define good mobilizers.一种自体干细胞动员的方法:尝试定义有效的动员剂。
Hematol Transfus Cell Ther. 2025 Jan-Mar;47(1):103688. doi: 10.1016/j.htct.2024.04.126. Epub 2024 Sep 7.
2
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.抗 CD38 单克隆抗体可损害多发性骨髓瘤患者 CD34+细胞的动员,并影响其集落形成能力。
Blood Transfus. 2024 Jul;22(4):328-337. doi: 10.2450/BloodTransfus.667.
3
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
来那度胺、硼替佐米和地塞米松联合依鲁替尼或伊沙妥昔单抗治疗初诊多发性骨髓瘤患者后的干细胞采集:来自 GMMG-HD6 和 -HD7 试验的单中心经验。
BMC Cancer. 2023 Nov 21;23(1):1132. doi: 10.1186/s12885-023-11507-9.
4
Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients.临床参数和诱导方案对多发性骨髓瘤患者外周血干细胞动员及采集的影响
Transfus Med Hemother. 2023 Jun 5;50(5):382-395. doi: 10.1159/000530056. eCollection 2023 Oct.
5
Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma-A Critical Toxicity Evaluation in the Modern Treatment Era.现代治疗时代多发性骨髓瘤放疗联合全身治疗的关键毒性评估
Cancers (Basel). 2023 May 25;15(11):2909. doi: 10.3390/cancers15112909.
6
Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.在新冠肺炎时代,与环磷酰胺或普乐沙福联合应用时,来那度胺诱导时间延长并不会显著影响多发性骨髓瘤患者干细胞采集。
Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e716-e729. doi: 10.1016/j.clml.2022.03.013. Epub 2022 Mar 28.